Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01922791
Other study ID # T166/2012
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date October 2013
Est. completion date March 2023

Study information

Verified date April 2023
Source Turku University Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

A randomized double-blind placebo controlled intervention study with pregnant obese women (n=440) will be conducted. The intervention will involve consumption of fish oil and/or probiotic capsules from early pregnancy until 6 months after delivery. The aim of the study is firstly to investigate the effects of the supplements on the risk of gestational diabetes mellitus and obesity in the women and secondly to modify the risk markers of allergy and obesity in children of the women. Also the underlying metabolic mechanisms will be investigated. Follow up visits at child's age of 5 to 6 years will be conducted to evalute long-term effects on maternal and child health. The aim is to investigate the impact of dietary intervention, diet, maternal overweight/obesity and gestational diabetes status as well as gut microbiota and metabolism during pregnancy on maternal and child's health, allergy and child neuropsychological development.


Recruitment information / eligibility

Status Completed
Enrollment 439
Est. completion date March 2023
Est. primary completion date December 2017
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group 18 Years to 45 Years
Eligibility Inclusion Criteria: - pregnant, less than 17 gestational weeks - overweight - healthy Exclusion Criteria: - Diabetes (type 1 or 2) - Coeliac disease - Increased bleeding tendency

Study Design


Intervention

Dietary Supplement:
Comparison of probiotics, fish oil and their combination to placebo
Double-blind randomized placebo controlled intervention

Locations

Country Name City State
Finland Turku University Hospital Turku
Finland University of Turku Turku

Sponsors (2)

Lead Sponsor Collaborator
Turku University Hospital University of Turku

Country where clinical trial is conducted

Finland, 

Outcome

Type Measure Description Time frame Safety issue
Other Body composition, growth, development and metabolic markers of the child 0 to 24 months of age
Primary Prevalence of gestational diabetes mellitus, GDM Assessed at gestational weeks 24-28
Primary Fasting glucose levels assessed at the third trimester of pregnancy
Primary Prevalence of allergy in child assessed at 12 and 24 months of age
Secondary Need for medication for management of gestational diabetes mellitus GDM (insulin or metformin) During pregnancy
Secondary Body composition of mother During and after pregnancy
Secondary Immunologic and metabolic markers During and after pregnancy
Secondary Fecal microbiota Before, during and after intervention
Secondary Fasting serum glucose (mmol/l) (mother/ child) Assessed at 5-6 years postpartum
Secondary Fasting serum insulin (mU/l) (mother/child) Assessed at 5-6 years postpartum
Secondary Number of women with prediabetes using criteria defined by American Diabetes Association Assessed at 5-6 years postpartum
Secondary Number of women with metabolic syndrome using criteria defined by The International Diabetes Federation Assessed at 5-6 yrs postpartum
Secondary Risk for Type 2 diabetes using questionnaire (mother) Assessed at 5-6 yrs postpartum
Secondary Serum high sensitive C-reactive protein (mg/l) (mother/child) Assessed at 5-6 yrs postpartum
Secondary Lipid metabolism (fasting cholesterol (mmol/l), fasting triglycerides (mmol/l), fasting HDL-cholesterol (mmol/l), fasting LDL-cholesterol (mmol/l) (mother/child) Assessed at 5-6 yrs postpartum
Secondary Serum metabolomics by NMR (mother/child) assessed at 5-6 yrs postpartum
Secondary Obesity by body mass index (mother/child) and body fat percentage by air displacement plethysmography (mother/child) Assessed at 5-6 yrs postpartum
Secondary Carotid intima media thickness by ultra sound (mother/child) Assessed at 5-6 yrs postpartum
Secondary Retinal microvasculature by digital retinal imaging (mother) Assessed at 5-6 yrs postpartum
Secondary Liver fat by ultra sound (mother) Assessed at 5-6 yrs postpartum
Secondary Liver health by ALAT (child/mother) Assessed at 5-6 yrs postpartum
Secondary Fecal microbiota composition (mother/child) Assessed at 5-6 yrs postpartum
Secondary Dietary intake of foods and nutrients and diet pattern calculated from food diaries, dietary quality index and food frequencies (assessed by questionnaires)/mother and child Assessed at 5-6 yrs postpartum
Secondary Eating behavior by Three Factor Eating Questionnaire, Neofobia and Comprehensive Feeding Practices Questionnaire, Child Feeding Questionnaire, Child Eating Behaviour Questionnaire (child) Assessed at 5-6 yrs postpartum
Secondary Motor development by Movement Assessment Battery for Children and by Developmental Coordination Disorder Questionnaire 2007 (DCDQ'07) (Child) Assessed at 5-6 yrs postpartum
Secondary Cognitive development by Cantab test and Wechsler Preschool and Primary Scale of Intelligence (child) Assessed at 5-6 yrs postpartum
Secondary Child effortful/emotionally-driven inhibition by the Forbidden Toy task and by Delay of gratification test (child) Assessed at 5-6 yrs postpartum
Secondary Social emotional assessment by Behavior Rating Inventory of Executive Functions (child) Assessed at 5-6 yrs postpartum
Secondary The child's social competence by Multisource Assessment of Children's Social Competence questionnaire and children's behavioral, social, and attention problems by the Child Behavior Checklist. (child) Assessed at 5-6 yrs postpartum
Secondary Infant temperament, Child Behavior Questionnaire (child) Assessed at 5-6 yrs postpartum
Secondary Child growth measured from weight (kg) and length (cm) Assessed at 5-6 yrs postpartum
Secondary Atopy by serum antigens and asthma by spirometry (child) Assessed at 5-6 yrs postpartum
Secondary Immunological cells from blood (child) Assessed at 5-6 yrs postpartum
Secondary Physical activity by questionnaires and activity monitor Assessed at 5-6 yrs postpartum
See also
  Status Clinical Trial Phase
Recruiting NCT04243317 - Feasibility of a Sleep Improvement Intervention for Weight Loss and Its Maintenance in Sleep Impaired Obese Adults N/A
Recruiting NCT04101669 - EndoBarrier System Pivotal Trial(Rev E v2) N/A
Terminated NCT03772886 - Reducing Cesarean Delivery Rate in Obese Patients Using the Peanut Ball N/A
Completed NCT03640442 - Modified Ramped Position for Intubation of Obese Females. N/A
Completed NCT04506996 - Monday-Focused Tailored Rapid Interactive Mobile Messaging for Weight Management 2 N/A
Recruiting NCT06019832 - Analysis of Stem and Non-Stem Tibial Component N/A
Active, not recruiting NCT05891834 - Study of INV-202 in Patients With Obesity and Metabolic Syndrome Phase 2
Active, not recruiting NCT05275959 - Beijing (Peking)---Myopia and Obesity Comorbidity Intervention (BMOCI) N/A
Recruiting NCT04575194 - Study of the Cardiometabolic Effects of Obesity Pharmacotherapy Phase 4
Completed NCT04513769 - Nutritious Eating With Soul at Rare Variety Cafe N/A
Withdrawn NCT03042897 - Exercise and Diet Intervention in Promoting Weight Loss in Obese Patients With Stage I Endometrial Cancer N/A
Completed NCT03644524 - Heat Therapy and Cardiometabolic Health in Obese Women N/A
Recruiting NCT05917873 - Metabolic Effects of Four-week Lactate-ketone Ester Supplementation N/A
Active, not recruiting NCT04353258 - Research Intervention to Support Healthy Eating and Exercise N/A
Completed NCT04507867 - Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III N/A
Recruiting NCT03227575 - Effects of Brisk Walking and Regular Intensity Exercise Interventions on Glycemic Control N/A
Completed NCT01870947 - Assisted Exercise in Obese Endometrial Cancer Patients N/A
Recruiting NCT06007404 - Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
Recruiting NCT05972564 - The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function Phase 1/Phase 2
Recruiting NCT05371496 - Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction Phase 2